Safety, Biodistribution, and Dosimetry of 123I-IMPY: A Novel Amyloid PlaqueImaging Agent for the Diagnosis of Alzheimer's Disease
Andrew B. Newberg1,
Nancy A. Wintering1,
Karl Plössl1,
John Hochold1,
Michael G. Stabin2,
Marianne Watson3,
Daniel Skovronsky4,
Christopher M. Clark3,
Mei-Ping Kung1 and
Hank F. Kung1
1 Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; 2 Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, Tennessee; 3 Department of Neurology, Alzheimer's Disease Center, and Center of Excellence for Research on Neurodegenerative Diseases, University of Pennsylvania, Philadelphia, Pennsylvania; and 4 Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania

View larger version (6K):
[in a new window]
|
FIGURE 1. Chemical structure of 123I-IMPY.
|
|

View larger version (31K):
[in a new window]
|
FIGURE 2. Representative anterior (left) and posterior (right) whole-body scans at 20 min (A), 26 h (B), and 48 h (C) after intravenous injection of 123I-IMPY.
|
|
Copyright © 2006 by the Society of Nuclear Medicine.